Introduction {#S1}
============

Molecular chaperones are important regulators of cellular homeostasis ([@B30]; [@B11]; [@B5]; [@B58]; [@B99]). The major chaperone, heat shock protein 90 (Hsp90), is a highly abundant and conserved protein, comprising of roughly 1--2% of the total proteome ([@B30]; [@B29]). Hsp90, like other Hsp family members, interacts directly with protein clients to maintain cellular organization ([@B30]; [@B11]; [@B58]). In particular, Hsp90 assists with the final maturation steps of client proteins, such as kinases ([@B77]; [@B120]).

In mammalian cells, Hsp90 requires partner proteins, termed co-chaperones, to assist with client triage ([@B112]; [@B101]). One of the well-studied Hsp90 co-chaperones is Cell Division Cycle 37 (Cdc37) ([@B33]; [@B115]; [@B73]). The Hsp90/Cdc37 complex interacts with approximately 60% of the kinome ([@B36]; [@B72]; [@B121]). Cdc37, a signal transducer, binds to a diverse set of kinase clients ([@B121]). Independent actions of Cdc37 have also been described. For example, the stability of a discrete Cyclin-dependent kinase 4 (CDK4) was reported to be dependent on Cdc37 levels, but not on the interaction of Cdc37 with Hsp90 ([@B113]).

Considerable efforts have been made toward defining the interactions of Hsp90 kinase co-chaperone Cdc37, but the majority of these studies have been performed in cancer models ([@B12]; [@B64]; [@B126]). However, many kinases that are regulated by Cdc37 have also been implicated in neurodegenerative disease-related pathways ([@B10]; [@B55]; [@B58]; [@B60]; [@B62]; [@B130]; [@B137]). Hsp90 has been suggested as a therapeutic target for these disorders, but Hsp90 inhibitors have faced many challenges in the clinic ([@B84]; [@B83]). Targeting Hsp90 co-chaperones, such as Cdc37, may represent an alternative strategy ([@B81]; [@B111]). Here, we describe the evidence supporting a role of Cdc37 as a molecular target in neurological disorders, such as Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD) disease.

The Hsp90/Cdc37 Complex Regulates Kinases {#S2}
=========================================

Kinases are critical regulators of cell cycle progression, signal transduction, and transcription regulation ([@B69]; [@B117]; [@B121]). Therefore, proteins that regulate kinases, such as Hsp90, have broad implications in disease pathogenesis. Hsp90 functions as a homodimer, through the C-terminal domain (CTD) dimerization, and is primarily characterized by its ATPase activity in the N-terminal domain (NTD) ([@B108]; [@B135]). Kinase interaction with Hsp90 generally promotes kinase stabilization and activity ([@B72]; [@B4]). The Hsp90 co-chaperone, Cdc37, is a ubiquitous protein that is required for efficient Hsp90-mediated maturation of kinases, such as CDK5, extracellular regulated kinase (ERK), and protein kinase B (Akt), by aiding their partnership with Hsp90 ([@B33]; [@B115]; [@B51]; [@B113]; [@B53]; [@B124]; [@B121]; [@B70]). Strong Hsp90-Cdc37 binders have been characterized to be less thermodynamically stable on their own, whereas clients that are more stable have reduced dependence on Hsp90/Cdc37 for maturation ([@B116]; [@B121]). During this interaction, Cdc37 binds clients using NTD residues, the middle domain of Cdc37 then associates with the NTD of Hsp90, and, finally, ATP binding causes Cdc37 to transition into the middle domain of Hsp90 to promote kinase changes ([@B73]; [@B122]; [@B121]). Additional roles for the Hsp90/Cdc37 complex have also been described. In fact, previous studies have demonstrated that the shuttling of kinases to Hsp90 can sheathe proteins from further activation or ubiquitination ([@B24]; [@B89]). Recent reports also suggest that the Hsp90/Cdc37 interaction is important in preventing activated kinase aggregation ([@B118]; [@B121]). Additionally, it should be noted that clients can be regulated through augmentation of Hsp90's C-terminal MEEVD domain ([@B95]; [@B108]; [@B121]). This region is known to interact with tetratricopeptide repeat domain containing co-chaperones, which can further affect client binding and regulation ([@B87]; [@B121]). One of these co-chaperones, the serine/threonine protein phosphatase 5 (PP5), has been shown to also regulate the activity of Cdc37 by altering its phosphorylation status at serine 13 ([@B120]). Related to this, casein kinase 1 ([@B35]) and casein kinase 2 ([@B79]) have been shown to alter Cdc37 phosphorylation through PP5 activation and through affecting the Hsp90/Cdc37 interaction, respectively. Interestingly, these casein kinases have also been implicated to have involvement in the pathogenesis of neurodegenerative diseases, including AD and PD ([@B93]).

While there are no small molecules that specifically target Cdc37 or the Hsp90/Cdc37 complex, both Celastrol and Withaferin A have been shown to be capable of disrupting the Hsp90/Cdc37 complex, along with targeting other pathways in the cell ([@B138]; [@B132]). Celastrol can disrupt recombinant Hsp90/Cdc37 interaction at 50--100 μM concentrations ([@B136]), while another study in a cell-based model showed 12.5 μM is sufficient ([@B92]). These studies suggest that the concentrations of Celastrol required to disrupt Hsp90/Cdc37 may vary between different model systems. It is also known that Celastrol at nanomolar dose shown to suppress the production of proinflammatory cytokines TNF-α and IL-1ß and improve cognitive processes ([@B3]). Celastrol has also been reported to affect Hsp90 through alternative mechanisms, including activation of the heat shock response ([@B129]), indirectly through redox imbalance ([@B105]; [@B56]), and, recently, Celastrol was shown to induce Hsp90 oligomerization ([@B134]). Celastrol is also capable of binding and triggering oligomerization of p23, an Hsp90 co-chaperone ([@B19]). Withaferin A is mostly studied for its anti-inflammatory properties ([@B78]). Thus, the effects of Celastrol and Withaferin A cannot be assumed to be only through Hsp90 and Cdc37, but instead may be partially mediated by the disruption of this complex. More recently, additional compounds have been reported including, Kongensis A, a possible necroptosis and inflammation inhibitor that can bind to Hsp90 and dissociate its interaction with Cdc37 ([@B63]), and platycodin D, which has anticancer and immune regulatory properties that was also shown to disrupt the Hsp90/Cdc37 complex ([@B66]). However, these drugs have not yet been tested in models of neurodegeneration.

Alzheimer's Disease {#S2.SS1}
-------------------

Alzheimer's disease is a progressive neurodegenerative disease and the most common form of dementia ([@B75]; [@B8]). While the cause of AD is still not completely clear ([@B31]; [@B107]; [@B42]), AD is hallmarked by the accumulation of protein aggregates, most notably plaques between neurons, rich in β-amyloid (Aβ), and intraneuronal tangles, composed mainly of tau protein. The aggregation of these proteins is not the only cause of AD, but they are each thought to contribute to the progression. In fact, there are numerous pathways implicated in the pathogenesis of AD, including multiple kinases that may promote or stabilize amyloid accumulation ([@B74]; [@B65]; [@B1]). Aβ can be affected by kinases directly ([@B97]) and also indirectly through the phosphorylation of the amyloid precursor protein (APP) ([@B20]), which can alter the cleavage dynamics and Aβ generation. In fact, multiple kinases have been linked to Aβ plaque production or stability including: CDK5, dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), Akt, ERK, Fyn, c-Abl, and glycogen synthase kinase 3α (GSK3α) ([@B94]; [@B23], [@B22]; [@B14]; [@B17]; [@B28]; [@B90]; [@B37]; [@B10]; [@B55]; [@B60]; [@B62]; [@B130]; [@B137]). Some of these kinases, for example, c-Abl, have been shown to alter Hsp90 phosphorylation as well as affect other Hsp90 co-chaperones, like Activator of Hsp90 ATPase protein 1 (Aha1) ([@B34]). Thus, the interactions between kinases, chaperones, and substrates is quite complex. Additionally, many of these kinases have been shown to be either regulated by Cdc37 ([@B40]; [@B51]; [@B114]) and/or be a Cdc37 interactor ([@B116]). Interestingly, even though Hsp90 inhibition shows protection in Aβ models ([@B21]; [@B88]), studies investigating the role of Cdc37 in Aβ pathogenesis have not been reported. However, Cdc37 is likely to at least have an indirect role on Aβ deposition and stability through the regulation of these important kinases.

Kinases are strongly implicated in tau pathogenesis, as tau is found in a hyperphosphorylated state in the AD brain ([@B18]; [@B109]). These kinases include: CDK5, DYRK1A, Akt, ERK/mitogen-activated protein kinase (MAPK), Fyn, c-Abl, GSK3β, protein kinase C (PKC), and the microtubule affinity regulating kinase 2 (MARK2), as well as Cdc37 ([@B47]; [@B76]; [@B12]; [@B125], [@B124]; [@B8]; [@B13]; [@B52]; [@B61]; [@B62]; [@B68]; [@B106]). Data from our group demonstrated that Cdc37 in collaboration with Hsp90 stabilized tau, and, inversely, reduced Cdc37 promoted tau clearance ([@B51]). These effects on tau are likely a combination of direct interactions as well as indirect effects on other kinases. In fact, CDK5 and Akt, which can also promote tau phosphorylation ([@B47]; [@B13]; [@B68]; [@B106]), are stabilized by Cdc37 ([@B51]). Akt activity inversely regulates GSK3β, which also phosphorylates tau ([@B48]; [@B125], [@B124]; [@B52]), but other pathways can also regulate GSK3β ([@B43]). Interestingly, GSK3β was recently reported to bind the Hsp90/Cdc37 complex ([@B49]).

Prior work from our group demonstrated that Cdc37 modulation did not robustly affect GSK3β stability *in vitro* ([@B51]). MARK2, another kinase known to regulate tau, displayed a similar lack of effect following Cdc37 regulation. DYRK1A, Fyn, and c-Abl have been implicated in a number of studies to regulate tau phosphorylation ([@B100]; [@B28]; [@B59]; [@B131]). All of these kinases have been shown to bind and/or be regulated by Cdc37 ([@B133]; [@B119]; [@B116]; [@B114]), however, the synergy between these proteins on tau regulation has not been investigated. Cdc37 may also affect tau phosphorylation through the regulation of MAPK and PKC ([@B40]; [@B39]), but the contribution of these kinases on tau phosphorylation is still under investigation. Some reports suggest that ERK activation, which is downstream of via MAPK, alters tau phosphorylation ([@B61]; [@B62]), while others have shown no effect ([@B86]). In many models, PKC has been reported to phosphorylate GSK3β, thereby inhibiting its ability to phosphorylate tau residues ([@B27]; [@B46]; [@B32]); however, PKC can directly phosphorylate tau residues ([@B12]).

Taken together, these data suggest that Cdc37 regulation can directly alter tau phosphorylation and stability as well as indirectly affect tau through other kinases, such as Akt, CDK5, but shows minimal effects on the regulation of GSK3β, MARK2, while the collaborative effects of Cdc37 with MAPK, PKC, DYRK1A, Fyn, and c-Abl on tau have yet to be determined. Celastrol reduced tau phosphorylation by inhibiting Hsp90 ([@B15]), which may be partially mediated by Cdc37 disruption. Overall, Cdc37 can regulate several pathways implicated in AD pathogenesis, including multiple that affect both Aβ and tau.

Parkinson's Disease {#S2.SS2}
-------------------

The second most prevalent neurodegenerative disease is PD, which involves a decline in motor as well as cognitive abilities ([@B102]; [@B41]). The cause of PD is not known, but has been primarily linked to a decline in mitochondrial function, oxidative stress, dysregulation of multiple signaling pathways, and the formation of Lewy bodies ([@B103]). Lewy bodies primarily consist of misfolded α-synuclein. It has been suggested by our previous work that Cdc37 does not globally alter α-synuclein stability ([@B51]), but instead may contribute to the regulation of α-synuclein phosphorylation, which is highly linked to its aggregation. It is unknown if Cdc37 directly alters α-synuclein phosphorylation, but likely affects known α-synuclein regulating kinases, which include the Src family of kinases (including Lck and Fyn), casein kinase, and G protein-coupled receptor kinases ([@B54]; [@B71]; [@B85]; [@B116]). In addition, Cdc37 may affect other pathways linked to PD pathogenesis.

Mitochondrial dysfunction has been strongly linked to PD ([@B91]). In fact, hereditary PD genes encode mitochondrial proteins ([@B103]; [@B67]). For example, the Parkin (PRKN)/PTEN-induced kinase 1 (Pink1) pathway, which is essential for mitochondrial quality control ([@B102]). Interestingly, several studies have demonstrated interaction with Hsp90/Cdc37 may be critical in the regulation of Pink1, by regulating Pink1 stability ([@B128]; [@B80]; [@B6]). Hsp90/Cdc37 interaction is also crucial for proper Pink1 processing and subcellular localization ([@B128]). However, contrary data has also been reported, which shows a PD-associated mutant Pink1 isoform is degraded too quickly and fails to bind Hsp90/Cdc37 ([@B80]).

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause PD ([@B38]; [@B26]). Although the function of LRRK2 is unknown, its kinase activity has been demonstrated to activate multiple signaling pathways that suggest it contributes to neurite outgrowth and cytoskeletal maintenance ([@B38]; [@B26]). Therefore, abrogating aberrant LRRK2 kinase activity is of interest in PD ([@B2]). Hsp90 inhibitors have been shown to be effective at preventing LRRK2 toxic gain of function, by disrupting LRRK2 from the Hsp90/Cdc37 complex ([@B127]). Withaferin A can also reduce LRRK2 levels, in part through inhibiting the Hsp90/Cdc37 interaction ([@B82]). Based on these evidences, the Cdc37/Hsp90 complex may be a reasonable target for drug discovery in PD.

Huntington's Disease {#S2.SS3}
--------------------

Huntington's disease is an inherited neurodegenerative disease that severely impacts motor function and often impairs cognition ([@B57]; [@B16]), which is caused by an autosomal dominant mutation in the huntingtin gene that gives rise to a CAG trinucleotide repeat expansion ([@B104]). This generates cytoplasmic and nuclear protein aggregates that cause disturbances of the cellular proteasome affecting several pathways and ultimately resulting in neurotoxicity ([@B98]; [@B16]). Hsp90 can interact with huntingtin protein ([@B6]), and inhibition of Hsp90 can block mutant huntingtin aggregation through inducing the heat shock response ([@B110]). Celastrol can also inhibit mutant huntingtin aggregation by a similar mechanism ([@B138]).

Similar to tau, Akt, which is altered in HD brain, can directly phosphorylate mutant huntingtin protein, which can protect against aggregation and neuronal toxicity ([@B45]). Downregulation of Akt has also been shown in a HD animal model ([@B25]). As mentioned above, the Hsp90/Cdc37 complex can impact Akt stability ([@B7]). Another pathway of interest in HD pathogenesis with relation to Cdc37 is the I kappa B kinase (IKK)/nuclear factor kappa-light-chain-enhancer (NFkB) inflammatory response, which can be chronically upregulated in HD ([@B98]; [@B9]). The IKK kinase complex is responsible for activating the NF[K]{.smallcaps}B transcription factor, which triggers expression of the inflammatory genes. Recruitment of Cdc37 to Hsp90 is required for proper IKK catalytic activation ([@B44]). Interestingly, IKK inhibitors show neuroprotection in a brain slice HD model ([@B96]). Celastrol can inhibit IKK ([@B61]), which is suggested to be a direct action, but it is possible that disruption of the Cdc37/Hsp90 complex may also contribute ([@B136]). Overall, these evidences suggest the Hsp90/Cdc37 complex deserves further investigation as a therapeutic target in HD.

Final Words {#S3}
===========

Overall, Hsp90 and Cdc37 regulates many neurodegenerative disease-linked proteins ([Figure 1](#F1){ref-type="fig"}). Experimental evidence suggests that client proteins may be differentially affected based on their strength of Hsp90/Cdc37 binding, which may allow for targeting a specific subset of clients without affecting the whole pool. Recent work has started to characterize these interactions ([@B121]), but additional studies are needed to better clarify these differences and how they are affected in disease. The ability to regulate many pathways through a single protein complex is exciting, but it is unlikely that any single protein complex will be the sole solution for any neurodegenerative disease. These diseases are very complex and may be more of a spectrum than individual disorders ([@B123]). However, additional research is still needed to better understand the benefits of targeting Cdc37, as well as other exciting targets, in these diseases. It is also important to note that there are other neurodegenerative diseases that were not discussed in this review, such as amyotrophic lateral sclerosis (ALS). In ALS, there are some unique pathways as well as many overlapping with those diseases discussed, including data to suggest the Hsp90/Cdc37 pathway ([@B50]). While the effects of Hsp90 inhibitors in neurodegenerative models of disease has been tested, the investigation of targeting Hsp90/Cdc37 is still underexplored. Celastrol and Withaferin A, along with Hsp90 inhibitors, like 17-AAG, albeit not specific to Cdc37, can regulate this interaction. Perhaps with the development of the next phase of Hsp90 inhibitors more tools will be available to target this complex ([@B83]). In addition, the recent discovery of novel drugs that regulate the Hsp90/Cdc37 interaction, like platycodin D and Kongensis A ([@B63], [@B66]), provides new avenues for investigation.

![Schematic representation of Hsp90/Cdc37 regulated major kinases and proteins linked to neurodegenerative diseases. AD, Alzheimer's disease; PD, Parkinson's disease; HD, Huntington's disease.](fnins-13-01263-g001){#F1}
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